The intense marketing of unproven stem cell interventions has become an international health concern. The authors offer resources and suggestions for physicians seeking to effectively counsel patients and respond to their questions about various stem cell therapies.
The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004
The winner’s curse — overestimating the value of an asset and therefore overpaying — is often associated with acquisitions of publicly-traded firms but not with private acquisitions. Using an event study methodology for over 22,000 private acquisitions of U.S. firms between 1985 and 2015, the authors examine a possible winner’s curse for such acquisitions, testing variables to determine what characteristics make a private company more likely to overestimate the asset's value.